Skip to content
AnalystLens

BOSTON SCIENTIFIC CORP 8-K Report, Executive Changes (Sep 23, 2026)

Reports
Leadership Changes
Filing Date
Filed September 23, 2026
Period End
September 21, 2026
Security
BSX
In the record · 2016–202610-K1310-Q328-K181

BSX filed 13 annual reports (10-K), 32 quarterly reports (10-Q) and 181 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Aug ’17Aug ’17
  2. Material agreement8-K · Nov ’19Nov ’19
  3. Leadership change8-K · Nov ’21Nov ’21
  4. Leadership change8-K · Nov ’25Nov ’25

01—Abstract

Summary

Summary of the 8-K filed September 23, 2026. Cited figures are marked; the original filing is the authoritative source.

Boston Scientific Corporation (BSX) has announced the upcoming retirement of Arthur C.

Butcher, Executive Vice President and Group President, MedSurg and Asia Pacific, effective January 1, 2027. This transition is a significant event for investors as Mr. Butcher has held a key leadership position within the company.

While he will be stepping down from his operational role, he is expected to serve as a senior advisor until February 26, 2027, ensuring a smooth handover and continuity. This advisory role will provide him with a prorated base salary of $780,000a.

02—Key points

Key Highlights

  1. Arthur C. Butcher, EVP and Group President, MedSurg and Asia Pacific, will retire effective January 1, 2027.
  2. Mr. Butcher will transition to a senior advisor role from January 1, 2027, through February 26, 2027.
  3. As a senior advisor, Mr. Butcher will receive his current annual base salary of $780,000, prorated.
  4. A Retirement Agreement is expected to be entered into with Mr. Butcher.
  5. Payments and benefits under the Retirement Agreement are anticipated to align with existing Company plans, including the Executive Retirement Plan, 2026 Annual Bonus Plan, and Long-Term Incentive Program.
  6. The filing indicates that Mr. Butcher's departure is voluntary, driven by his decision to retire.

03—Questions

Frequently Asked Questions

  1. What is the immediate impact of Arthur C. Butcher's retirement on Boston Scientific?

    The immediate impact is the planned departure from his operational role as Executive Vice President and Group President, MedSurg and Asia Pacific, effective January 1, 2027. However, continuity is being maintained through his advisory role until February 26, 2027, to facilitate a smooth transition.

  2. What compensation and benefits will Arthur C. Butcher receive during his advisory period and upon retirement?

    During his advisory period, Mr. Butcher will receive his current annual base salary of $780,000, prorated through February 26, 2027. Upon retirement, he is expected to receive payments and benefits consistent with those outlined in the Company's Executive Retirement Plan, 2026 Annual Bonus Plan, and Long-Term Incentive Program, as well as existing equity awards.

  3. Does the company plan to appoint a replacement for Arthur C. Butcher's role?

    This 8-K filing does not explicitly state plans for a direct replacement for Mr. Butcher's role. However, given his substantial responsibilities, investors should anticipate future communications from the company regarding leadership appointments or restructuring of these divisions.

  4. Is this retirement indicative of any underlying issues within the MedSurg or Asia Pacific divisions?

    The filing states that Mr. Butcher "has decided to retire," suggesting this is a personal decision. There is no information within this filing to indicate underlying issues within the MedSurg or Asia Pacific divisions. Investors should monitor future performance reports and executive communications for any insights.

04—Continue

← View all 8-K filings